Tirzepatide Dosage: Amounts Used in Studies and Care
A low first dose gives the stomach time to settle
A weekly shot can upset the stomach at first. The first amount on the FDA label is low. It leaves four weeks between each increase. That pause gives the stomach time to settle. The label and studies set 15 mg as the highest amount. Each week, the medicine is placed beneath the skin.
About five days pass before half leaves the body. Some medicine remains when the next weekly shot is due. Here you can see the label amounts and those tested in studies. Your prescriber picks the amount for you.
The Tirzepatide dose rose every four weeks
The large final studies, called phase 3, raised the Tirzepatide dose in steps. They began at 2.5 mg. That weekly amount stayed the same for four weeks. Later steps also came four weeks apart: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg. The FDA label uses this plan for weight care and type 2 diabetes [18].
Long-term study amounts were 5 mg, 10 mg, and 15 mg each week. SURMOUNT-1 found average weight changes of -15.0%, -19.5%, and -20.9% over 72 weeks [4]. For type 2 diabetes, SURPASS-2 tested those three amounts too. At 5, 10, and 15 mg, the months-long sugar test fell 2.01, 2.24, and 2.30 points [3]. These points aren’t home meter readings.
SURMOUNT-5 raised each person’s amount only while side effects stayed bearable. The final amount was 10 mg or 15 mg [5]. In daily care, a prescriber may stop an increase when harm outweighs benefit.
You can read the study plan, but it isn’t a dose choice for you.
Tirzepatide dosage keeps medicine in the blood all week
FDA approval covers Tirzepatide placed under the skin. Study staff used the thigh, belly, or upper arm. They changed the spot each week. Sold forms include one-dose pens and vials. Both need cold storage.
About five days pass before half the drug leaves [1][7]. A fat piece helps it travel with albumin, a common blood protein. The body then clears Tirzepatide more slowly. One study included people of many body sizes. Weight, age, sex, or race did not change the weekly timing enough to call for a different amount [7].
After roughly four to five weeks, the amount left between shots becomes steadier. Each new shot then replaces much of what the body cleared. This doesn’t mean the full effect has arrived. In SURMOUNT-1, weight began falling in the first four weeks and kept falling through 72 weeks [4].
Your blood amount and response may differ.
Tirzepatide dosage depends on the approved use
The FDA label gives plans for three approved uses.
Approval came in May 2022 for type 2 diabetes. The first weekly amount is 2.5 mg. The label then uses four-week steps. The highest amount is 15 mg [18].
November 2023 brought approval for weight care. Doctors use body mass index, a score made from height and weight. A score of 30 or more can count. So can 27 with a weight-linked health problem. The same step plan applies. Benefit and side effects guide the long-term amount. The top weekly amount is 15 mg [18][9].
Tirzepatide also treats serious sleep apnea when obesity is present. SURMOUNT-OSA found fewer breathing stops each hour as weight fell [12].
Low blood sugar can occur with insulin or some diabetes pills. Those drugs can also draw insulin from the pancreas. The label says doctors may lower the other drug [18]. Pills used for birth control may give less protection when Tirzepatide starts or rises. At those times, the label calls for birth control that isn’t swallowed, such as condoms [18][28].
Your prescriber applies these label rules to you.
The Tirzepatide injection goes under the skin
Every Tirzepatide injection in the studies went under the skin. People used it once a week on the same day. Meals didn’t change that timing.
The shot spot may turn red, itch, feel sore, bruise, or form a small lump. One FDA list held over 19,000 reports about shot spots from 2022 to early 2025 [34]. Doctors, patients, and others can send reports to that list. It never said how many people used the drug, so an ordinary chance can’t be worked out. Most marks cleared within two to five days. Study directions called for a new spot each week.
The same FDA list most often mentioned use of the wrong amount [34]. That means too much or too little medicine may have been used. The list didn’t say whether a pen, vial, clinic, or patient caused the mistake. It also gave no rate among all users. That is why the pen or vial directions matter.
Tirzepatide isn’t approved as a pill. It isn’t approved for a vein or muscle shot. These findings came from shots under the skin.
The report can’t give your chance of a mark.
Tirzepatide side effects rose as the dose rose
Nausea led the common problems. Vomiting and bowel trouble followed. In SURMOUNT-1, these problems appeared most during dose increases. Serious harm occurred in about 6% taking Tirzepatide and 5% taking placebo [4].
One review covered obesity without diabetes. Tirzepatide brought more nausea and bowel trouble than placebo [17]. Another review used FDA reports from 2022–2025. Half began within about 16 days of starting treatment. Half began later. Most began in the first three months [20].
Nine studies and 9,871 people went into one review. It did not find more cases of a swollen pancreas overall. Researchers used a 95% range to show doubt. The pancreas span was wide, so the finding was uncertain. Gallbladder trouble and trouble with bile, the fluid that helps digest fat, did rise. The bile result had a narrower 95% range, so researchers had less doubt. The paper still didn’t give plain head counts for either harm [6].
A large review did not find more sudden kidney harm overall. It also did not find more thyroid cancer or uneven heartbeat overall. Rare harm could still be missed. The strongest warning for drugs that copy GLP-1 came from rats and mice. Human studies haven’t proved that harm [21].
Open Tirzepatide effects for each safety note and source.
Your side effects may differ from these reports.